Link Biologics completes IND-enabling preclinical programme for LB001, a first-in-class novel therapy for dry eye disease
- Completion of key IND-enabling activities represents a major development milestone for LB001
- IND submission remains on track for Q1 2027, followed by initiation of a Phase 1/2 clinical study
- Manufacturing scale-up completed, providing supply for planned clinical studies
London, UK – 5 November 2026 – Link Biologics (“Link” or “the Company”), the biotech developing first-in-class TSG-6-based therapies that have a unique combination of anti-inflammatory, tissue-protective and tissue-reparative properties, today announces the successful completion of its IND-enabling preclinical programme for LB001 (Link_TSG6), its lead asset, for the treatment of moderate to severe dry eye disease (DED).
